Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin-Reference-Cited by-同舟云学术

Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin

Published:2014-11-23 Issue:2 Volume:101 Page:119-125
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Mitsuguro Mana,Okamoto Akira,Shironouchi Yoshie,Sano Michitaka,Miyata Shigeki,Neki Reiko,Araki Tatsuya,Hamamoto Takayoshi,Yoshimatsu Jun,Miyata Toshiyuki

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-014-1702-z.pdf

Reference17 articles.

1. Basu D, Cade J, Gallus A, Hirsh J. A prospective study of value of monitoring heparin treatment with activated partial thromboplastin time. N Engl J Med. 1972;287:324–7.

2. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med. 2003;138:720–3.

3. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin:the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:188S–203S.

4. Garcia DA, Baglin TP, Weitz JI, Samama MM. American College of Chest Physicians. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based clinical practice guidelines. Chest. 2012;141:e24S–43S.

5. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the APTT: time for a fresh look. Thromb Haemost. 2006;96:547–52.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between ABO blood types and peripherally inserted central catheter-related venous thrombosis for patients with cancer: A retrospective 7-year single-center experience and meta-analysis;PLOS ONE;2024-07-01

2. Are shortened aPTT values always to be attributed only to preanalytical problems?;Diagnosis;2024-05-03

3. Interference of oral anti-Xa anticoagulants during monitoring of unfractionated heparin treatments: practical and future attitudes;Annales de Biologie Clinique;2024-04

4. Monitoring of Argatroban in Critically Ill Patients: A Prospective Study Comparing Activated Partial Thromboplastin Time, Point-of-Care Viscoelastic Testing with Ecarin Clotting Time and Diluted Thrombin Time to Mass Spectrometry;Anesthesiology;2023-10-03

5. Hemostatic disorders associated with extracorporeal membrane oxygenation;Minerva Anestesiologica;2023-06